To investigate the effects of pharmacological delay with insulin-like growth factor-1 (IGF-1) on skin flap survival.
Introduction
One of the basic practices in plastic and reconstructive surgery is reparation of tissue defects caused by trauma, tumor, congenital abnormalities, or other incidents. The best functional and aesthetic results are achieved using flaps for this purpose. Flaps are classified as two subgroups according to the vascular supply: random-pattern skin flaps (supplied by subdermal-dermal plexus) and axial-pattern skin flaps (supplied by a direct cutaneous artery and vein located in subcutaneous tissue). Extending flap survival and decreasing amount of flap necrosis has been important subjects in surgical research. Surgical delay is the mostly used method for lessening the flap necrosis. Main disadvantages of delay are multiple interventions and long hospital stay. Many agents have been discussed for a single step delay process 1 .
Insulin-Like Growth Factor-1 (IGF-1) has growth stimulant effect via increasing the proliferation of many cell types including skeletal muscle, cartilage, bone, liver, kidney, neural, skin, hematopoietic, and lung cells. Circulating IGF-1 increases anabolic effects like protein synthesis, peripheral glucose uptake, glycogen synthesis, neuron survival, myelin synthesis, and bone formation [2] [3] [4] [5] [6] [7] . In addition, it decreases some catabolic effects such as protein degradation in muscles 8 .
In the present study, we aimed to detect experimentally whether the features of IGF-1 have any positive effect on the flap survival.
Methods

Support of institutional Scientific Research Projects
Commission and approval of Local Ethical Board on Animal Studies were provided for this experimental study.
Thirty Sprague-Dawley rats ranging 250-300 grams were employed in the research. Standard room conditions were maintained with a temperature of 24°C, 12 hours illuminated -12
hours dark conditions and equal cage sizes. Two rats resided in each cage that had readily available rat food and tap water. micrograms of IGF-1 in 20 ml of distillated water was prepared.
It was administered subcutaneously to the experimental group rats as 15 micrograms/0,3 ml in a calculated dose of 6 micrograms/100 grams. Planned flap was divided in 6 equal pieces, and midpoints of each portion were determined as injection points ( Figure 1 ). 
Surgical procedure
Anesthesia was accomplished with intramuscular injection of 100 mg/kg ketamine hydrochloride and 10mg/kg xylazine hydrochloride to rats. After the subjects had anesthetized, trichotomy of donor areas were performed using an electrical razor. Rats were stabilized to the operation table in prone position.
Povidone iodine was used for the cleaning of donor area. A 3x9 cm 
Analyses
Flaps were followed up after the surgery; necrosis was arisen in the distal parts beginning from the second day. Demarcation of necrotic areas ended at postoperative seventh day. Rats were photographed with a digital camera (Sony DSC W 100, Sony Corporation, Tokyo, Japan). Tissue and blood samples were collected for histological and biochemical examinations. Macroscopic analyses were carried out at postoperative seventh day in all groups. At the end of the seventh day, rats were placed to the table in prone position. All flaps were photographed from equal distances. Survived flap areas and whole flaps were measured by ImageJ program (Wayne Rasband, NIH) from the pictures. Survived flap area / whole flap was determined as percentiles (%) (Figure 3 ). Because of the wound contracture, flap area at the end of the seventh day was smaller than its initial size. Even though flaps were contracted somewhat, percentile evaluation of survived flap area to whole flap ratio provided standardized results. Vascular endothelial growth factor (VEGF) levels were measured from the cardiac blood and 1 cm 2 of tissue samples which had taken from flap demarcation line using Elisa method. Tissue samples were washed by cold saline and kept at -20 0 C of temperature. Thereafter, they were homogenized with suitable buffer. VEGF level from the supernatant part was studied by Elisa method after the centrifugation of homogenized buffer.
For the histological examination, collected tissue samples were fixed in 10% phosphate buffered (pH 7.2) formaldehyde solution for 48 hours. Then, they were blocked in paraffin after alcohol and xylene applications. Specimens with 5-6 mm thickness from those blocks were taken to adhesive slides. Slides were stained by avidin-biotin-peroxidase complex (ABC) method. After the deparaffinization and dehydration processes, slides were transferred to phosphate buffered salty solution (PBS, 0.1 M, pH 7.4). To resolve the activity of endogenous peroxidase activity, slides were kept in 3% of H 2 O 2 solution for 10 minutes. They were boiled in a 0.01 M and pH=6.0 of citrate buffer in a microwave to expose antigens. Specimens were limited with a hydrophobic pencil. Horse serum was applied for endogenous serum blocking and incubation was performed at 37 0 C for 10 minutes. To identify the vascular endothelium, rabbit anti-CD31 (Pecam-1) antibody with 1/500 dilution was dribbled to the tissues. They were washed after the incubation at 37 0 C for two hours in humidity chamber.
Thereafter, ABC kit applications were started. Biotin conjugated with peroxidase was dribbled and incubated at 37 0 C. Slides were washed and treated with the red coloring ABC peroxidase substrate. When the reaction was formed, they were taken to distillated water and the reaction was ended. Specimens were closed by lamella using aqueous glue and examined in light microscope. Vessels stained by CD31 antibody were counted morphometrically in 1 mm 2 area with x800 magnification (Figure 4 ). 
Results
Macroscopic analysis
Photographs of groups are presented in Figure 5 . Flap survival rates were 43.55 ± 16% in group 1 (control group),
21.40 ± 8% in group 2 (sham group), and 43.12 ± 14% in group
(experiment group). No significant difference was detected
between group 1 and 3 (p = 0.997). Differences between group 2 and group 3, and group 1 and group 2 were statistically significant (p = 0.001). Table 1 shows the statistical results of survived flap area / whole flap rates between groups as percentiles. 
Biochemical analysis
Tissue VEGF levels (pg/mg protein) were found 17.75± 3.57; 18.65 ± 4.84; and 19.72 ± 7.01 in group 1, 2, and 3, respectively. No statistically significant difference was detected between groups (p>0.05).
Plasma VEGF levels (pg/ml) of groups were as follows: 6.38 ± 2.09; 8.05 ± 2.42; and 6.23 ± 2.02 in group 1, 2, and 3, respectively. We found no significant difference between groups.
Histological analysis
In Figure 6 , selected samples of histological specimens are presented. Number of vessels were 73.10 ± 21.86; 78.40 ± 33.78; and 76.20 ± 39.77 in group 1, 2, and 3, respectively. There was no significant difference between groups (p>0.05). Previous studies observed IGF-1 increases re-epitelization by keratinocyte migration, collagen deposition by fibroblast proliferation, and granulation tissue by neovascularization [10] [11] [12] .
Neovascularization is a known mechanism that advances flap survival in the delay process 13 . In the present study, we hypothesized that IGF-1 could pharmacologically provide neovascularization and increase the flap survival. We found no significant difference between experimental and control groups for skin flap survival, to increase its local effect on flap survival in the present study.
Kucuk et al. 17 , based on effects of growth hormone on wound healing, investigated the effectiveness of infused recombinant human growth hormone on fistula closure and histopathological changes in healing tissue following pharyngocutaneous fistula formation in Sprague-Dawley rats after pharyngoesophagotomy. In their study, while control group received no treatment, experiment group were administered a subcutaneous injection of recombinant human growth hormone daily. They showed that it was effective for fistula closure by increasing collagen formation and epithelisation in a rat model.
Similar to ours, the authors used a subcutaneous route of growth hormone application. However, they made the microscopical and macroscopical examinations on 14th day of the experiment.
Limited time window in our study (seven days) might have yielded the insignificant results although the similarity of other methods with the above cited study.
Gu et al. 18 established subcutaneous injection of recombinant human growth hormone in their study with eight patients with enterocutaneous fistula. After 7 days, they showed Diminishing edema can increase flap survival. Kurtz et al. 21 showed IGF-1 had an anti-inflammatory effect other than neutrophil migration and accelerated the healing duration.
We used IGF-1 subcutaneously one week before the surgery. 
